However, intriguingly, cancer samples with an immune-active profile expressed relatively less well explored checkpoint markers, such as PDL2, BTN3A, TIGIT, and CD73; their dual stimulatory/inhibitory role in the immune response regulation attracts growing interest in view of their diagnostic/therapeutic potential. This evidence concerns the gene PDCD1LG2 and cancer.